Results 31 to 40 of about 22,618 (258)

The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]

, 2016
Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea, Diaz, Graciela Susana, Recouvreux, Maria Victoria, Rifkin, Daniel B.   +3 more
core   +2 more sources

Etiopathogenetic features of hyperprolactinemia in childhood

Zdorovʹe Rebenka, 2021
In recent years, the problem of hyperprolactinemia in children remains relevant because it is one of the most common pathologies of the hypothalamic-pituitary system, causing impaired fertility and reproductive function in adulthood.
O.E. Abaturov, H.O. Nikulina, O.O. Rusakova   +2 more
doaj   +1 more source

Antipsychotic‐Induced Hyperprolactinemia [PDF]

, 2009
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90238/1/phco.29.1.64 ...
Bostwick, Jolene R., Ellingrod, Vicki L., Guthrie, Sally K.   +2 more
core   +1 more source

Corticotropinoma as a Component of Carney Complex. [PDF]

, 2017
Known germline gene abnormalities cause one-fifth of the pituitary adenomas in children and adolescents, but, in contrast with other pituitary tumor types, the genetic causes of corticotropinomas are largely unknown.
Chittiboina, Prashant, Dimopoulos, Aggeliki, Faucz, Fabio R, Hernández-Ramírez, Laura C, Kay, Denise M, Lane, John, Lodish, Maya B, Mills, James L, Pankratz, Nathan, Stratakis, Constantine A, Tatsi, Christina, Valdés, Nuria   +11 more
core   +2 more sources

Hyperprolactinemia [PDF]

, 2009
This issue of eMedRef provides information to clinicians on the pathophysiology, diagnosis, and therapeutics of ...
Jones, Daniel
core   +1 more source

Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study

, 2014
Objective: Effects of conventional and atypical antipsychotics on bone mineral density (BMD) and serum prolactin levels (PRL) were examined in patients with schizophrenia.Methods: One hundred and sixty-three first-episode inpatients with schizophrenia ...
Cao, Bingyu, Hou, Ruihua, Jian, Jia, Mi, Guolin, Qiu, Huimin, Tang, Maoqin, Wang, Mengxin   +6 more
core   +1 more source

The value of PRL in predicting prolactinοma in hyperprolactinemic PCOS [PDF]

, 2018
Background To identify a serum prolactin (PRL) cut‐off value indicative of a PRL‐producing adenoma in women with Polycystic Ovarian Syndrome (PCOS) and hyperprolactinemia and characterize such patients.
Angelousi, Anna, Dimitriadis, Georgios K., Kaltsas, Gregory, Kyritsi, Eleni Magdalini, Mehta, Hiten, Mytilinaiou, Maria, Randeva, Harpal S., Shad, Amjad   +7 more
core   +1 more source

Olanzapine-Induced Hyperprolactinemia: Two Case Reports

Frontiers in Pharmacology, 2019
Background: Hyperprolactinemia is a common consequence of treatment with antipsychotics. It is usually defined by a sustained prolactin level above the laboratory upper level of normal in conditions other than that where physiologic hyperprolactinemia is
Pedro Cabral Barata, Mário João Santos, João Carlos Melo, Teresa Maia   +3 more
doaj   +1 more source

Medical treatment of prolactinomas. [PDF]

, 2011
Prolactinomas, the most prevalent type of neuroendocrine disease, account for approximately 40% of all pituitary adenomas. The most important clinical problems associated with prolactinomas are hypogonadism, infertility and hyposexuality.
A Barlier, A Beckers, A Chattopadhyay, A Ciccarelli, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Di Sarno, A Di Sarno, A Klibanski, A Liuzzi, A Saveanu, A Wakil, A Zárate, AG Lania, AI McCormack, AM Colao, Annamaria Colao, AP Heaney, BM Biller, C Di Somma, C Ferrari, C Rasmussen, C Wang, CY Choong, D Cheung, D Dallabonzana, D McCall, DA De Luis, DA Sisam, DG Johnston, DG Johnston, E Delgrange, E Delgrange, E Delgrange, E Valassi, EJ Lee, F Andersohn, F Bogazzi, F Bogazzi, FF Casanueva, G Raverot, G Schettini, G Zada, GA Kaltsas, HE Turner, I Shimon, I Shimon, J Gorski, J Kharlip, J Schlechte, J Verhelst, J Webster, JC Williams, JJ Orrego, JK Devin, JM Wilson, JP Singh, JS Bevan, JW van't Verlaat, K Thapar, K Thapar, KJ Gräf, L Vilar, LB Nachtigall, LC Tan, LD George, LJ Hofland, M Biswas, M De Rosa, M De Rosa, M De Rosa, M Esteller, M Giusti, M Kars, M Kars, M Lafeber, M Muratori, M Ono, M Rocheville, M Steiger, MC Koppelman, MD Bronstein, ME Molitch, ML Vance, MP Gillam, MP Gillam, MS Huda, N Herring, OM Dekkers, P Fainstein Day, P Lancellotti, P Moriondo, PG Crosignani, PU Freda, R Homburg, R Schade, R Zanettini, RB Rothman, S Cannavò, S Ekeblad, S Karunakaran, S Mohammed, S Vallette, SG Ren, Silvia Savastano, SW Lamberts, SW Lamberts, T Mindermann, T Sabuncu, T Tan, V Goffin, VG Rasmussen, VQ Passos, W Winkelmann, WJ Jeffcoate, WS Maxson, Y Greenman   +131 more
core   +1 more source

Bone turnover markers in medicamentous and physiological hyperprolactinemia in female rats [PDF]

, 2014
Background/Aim. There is a lack of data on the effects of prolactin on calcium metabolism and bone turnover in hyperprolactinemia of various origins.
Pešić Milica, Radojković Danijela, Ristić Tatjana   +2 more
core   +1 more source